DGAP-News

RedHill Biopharma Announces Research Collaboration with NIH for Potential Ebola Treatment

DGAP-News: RedHill Biopharma Ltd. / Key word(s): Agreement
RedHill Biopharma Announces Research Collaboration with NIH for Potential
Ebola Treatment

19.07.2016 / 09:00
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Press Release

RedHill Biopharma Announces Research Collaboration with NIH for Potential
Ebola Treatment

TEL-AVIV, Israel, July 18, 2016 RedHill Biopharma Ltd. (NASDAQ: RDHL)
(TASE: RDHL) ("RedHill" or the "Company"), a biopharmaceutical company
primarily focused on development and commercialization of late clinical-
stage, proprietary, orally-administered, small molecule drugs for
inflammatory and gastrointestinal diseases and cancer, announced the
signing of a research collaboration agreement with the U.S. National
Institute of Allergy and Infectious Diseases (NIAID), part of the National
Institutes of Health (NIH), intended to evaluate RedHill's proprietary
experimental therapy for the treatment of Ebola virus disease.

The new research collaboration follows encouraging results from preliminary
non-clinical studies conducted in conjunction with the NIAID using
RedHill's proprietary experimental therapy. The objectives of the new
research collaboration between RedHill and NIAID are to evaluate survival
outcome and assess disease severity through comparison of viral loads and
cytokine levels in active treatment arms and placebo. If successful, this
study is intended to provide supportive data for discussions with the U.S.
Food and Drug Administration (FDA) for potential use of the Animal Rule
pathway for approval. According to FDA guidelines, approval under the
Animal Rule can be pursued only if human efficacy studies cannot be
conducted because the conduct of such trials is unethical or not
feasible[1].

Ebola virus disease is a severe and often fatal illness which can cause
severe hemorrhagic fever in humans and has a mortality rate ranging from
25% to 90%[2]. There is currently no FDA approved treatment for Ebola virus
disease.

About RedHill Biopharma Ltd.:
RedHill Biopharma Ltd. (NASDAQ/TASE: RDHL) is a biopharmaceutical company
headquartered in Israel, primarily focused on the development and
commercialization of late clinical-stage, proprietary, orally-administered,
small molecule drugs for the treatment of inflammatory and gastrointestinal
diseases and cancer. RedHill's current pipeline of proprietary products
includes: (i) RHB-105 - an oral combination therapy for the treatment of